[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Ethics::
peer-review::
Indexing::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Journal DOI

AWT IMAGE

..
Copyright Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 
This Journal is licensed under a Creative Commons Attribution-NonCommercial 4.0
..
:: Volume 6, Issue 1 (1-2004) ::
J Babol Univ Med Sci. 2004; Volume 6 Back to browse issues page
Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward
M Malek * , M Fakharian Kashani
Abstract:   (11234 Views)
Background and Objective: Renal osteodystrophy is one of the most important complications of ESRD (End Stage Renal Disease). Prescription of calcium, low phosphate diet and rocaltrol are essential in these patients. The aim of this study was to determine the prevalence of renal osteodystrophy and secondary hyperparathyroidism in ESRD patients were covered by Semnan- Fatemieh hemodialysis center and detect the oral rocaltrol pulse response on secondary hyperparathyroidism and renal osteodystrophy in some of these patients. Methods: In first step, 31 patients with ESRD checked for serum calcium (Ca2+) phosphorous (P), alkaline phosphatase and iPTH (IRMA) and bone deformity in bone x-ray from 2000-2001. In second step, 12 patients were categorized in three groups according to iPTH level and treated with 1, 2, 4 microgram oral-rocaltrol pulse, three times a week for 6 months, respectively. Then Ca2+, P, alkaline phosphatase, iPTH levels and bone graphy compared with before treatment results. Findings: From 31 patients with age average 52±17.7 and hemodialysis duration average 36±22.3 months, 3.5 Percent had Ca2+ level equal or higher than 10.4 mg/dl, 77.3 percent had P level equal or higher than 4.5 mg/dl, 80.6 percent had iPTH level higher than 120 pg/ml and 72.4 percent had alkaline phosphatase level higher than 175 Iu/l. No meaningful correlation observed between hemodialysis duration with serum Ca2+, P and alkaline phosphatase level. In 12 patients treated with oral rocaltrol pulse, meaningful differences observed only between serum iPTH level before and after treatment (P<0.003). Conclusion: In most studied patients, serum P and iPTH level was extremely high that suggest poor control of P and hyperparathyroidism. Oral rocaltrol pulse prescription for 6 months decreased iPTH level but had no effect on Ca2+, P and alkaline phosphatase.
Keywords: Secondary hyperparathyroidism, Renal osteodystrophy, Hemodialysis, Rocaltrol, iPTH, Oral pulse
Full-Text [PDF 464 kb]   (1814 Downloads)    
Type of Study: Research | Subject: Biochemical
Accepted: 2014/05/31 | Published: 2014/05/31


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Malek M, Fakharian Kashani M. Treatment results with oral Rocaltrol pulse among patients with secondary hyperparathyroidism in hemodialysis ward. J Babol Univ Med Sci 2004; 6 (1) :32-37
URL: http://jbums.org/article-1-2736-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 6, Issue 1 (1-2004) Back to browse issues page
مجله علمی دانشگاه علوم پزشکی بابل Journal of Babol University of Medical Sciences

The Journal of Babol University of Medical Sciences is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Persian site map - English site map - Created in 0.05 seconds with 43 queries by YEKTAWEB 4642